Demant

The Demant share climbed about 3.5% today after BofA Securities raised its rating from "Underperform" to "Buy" and increased the price target from DKK 170 to DKK 280. BofA justified the upgrade with stronger market growth in the first quarter, improved demand for the Oticon Zeal product, raised EPS forecasts for 2026 and 2027, and lower capital costs. The revaluation pushed the stock toward the new price target and supports a recovery thesis for Demant. » Mere på de.investing.com

Demant reports Q1 2026 revenue of USD 6.25 billion, 2.46% above the USD 6.1 billion forecast. Total growth was 16%, driven by 6% organic growth and 10% acquisition-driven growth (mainly from the acquisition of KIND); EPS met expectations. Strong sales in North America and Europe and the launch of Oticon Zeal lifted the gross margin, and the stock rose 0.97% after hours to USD 209.2. Management confirms the 2026 outlook and remains confident about further product launches in the second half of the year. » Mere på de.investing.com

Demant reported Q1 2026 revenue of USD 6.25 billion, exceeding the USD 6.1 billion forecast. Drivers were 6% organic growth and roughly 10% acquisition-driven growth following the integration of KIND, as well as the product launch of Oticon Seal, which led to an expansion of gross margin. The stock rose 10.9% to USD 232 after the announcement. Management confirmed the full-year guidance for organic growth of 3–6% and an EBIT range of DKK 4.1–4.5 billion, but cited currency risks and potential market saturation as challenges. » Mere på de.investing.com